15.04.2013 - French green plastics company Carbios has secured exclusive patent rights from a collaboration with the National Institute for Agricultural Research.
The five-year collaboration of Carbios (Clermon-Ferrant) and INRA (Paris) at the Toulouse White Biotechnology (TWB) research centre is part of the €22m THANAPLAST™ private-public consortium on plastics, comprising the CNRS, INRA, the Université de Poitiers, Deinove, the Barbier Group, and the Limagrain Group.
The Carbios-INRA project will focus on the development of bioprocesses for recovering plastic waste and producing economically competitive bio-based polymers. The interdisciplinary collaboration will include R&D staff from TWB, the 3BCar Carnot Institute and two INRA groups. The INRA groups will focus on enzyme screening, enzymatic catalysis and cell engineering.
Carbios is developing solutions for transforming the global supply of over 100 million tons of plastic waste into a novel, high-quality, renewable raw material for the plastics industry. The company offers a viable economic alternative to the depletion of agricultural resources and the rarefaction of fossil fuels.
Carbios CEO Jean-Claude Lumaret commented that "although Europe generates almost 25 million metric tons of plastic waste each year, only 20% of that is recycled. The recovery of such an important renewable resource is a key business issue. We are delighted to have signed this partnership agreement with LISBP and Micalis - two INRA R&D groups that are internationally renowned for their know-how and expertise in enzymatic bioprocesses. By combining our skills and resources, the resulting synergy will be an impressive driver for innovation and the development of breakthrough industrial bioprocesses".
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.